Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Payers

How extended periods of suppressed utilization and a regulatory pause on record collection may influence plans' anticipated results next year.

Principal, Health and Life Sciences, Organizational Effectiveness, Oliver Wyman
Senior Advisor, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

The pandemic may transform the foundation that innovative collaborations are based on.

Partner, Health & Life Sciences, Oliver Wyman
Associate, Health & Life Sciences, Oliver Wyman
Principal, Oliver Wyman
Senior Consultant, Oliver Wyman

Executives discuss the COVID-19 financial fallout and what future subsequent peaks might look like for health systems.

Market dynamics are ripe for M&A activity. But before being enticed by a mirage, leaders must revisit old lessons.

Principal, Health and Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

We must focus on diligence and safety, and balance that with maintaining as much normalcy as possible.

Partner and CMO, Health and Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

A model of payment transformation in Southeast Michigan is gaining traction.

Senior Vice President, Health Care Value, BCBSM
Senior Vice President, Network and Provider Partnerships, BCBSM

Here's how we did on last year's predictions and what emerging trends to expect next.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Head of Health & Life Sciences, Asia Pacific, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Manager, Health & Life Sciences, Oliver Wyman

In our rearview mirror is a ten-year stretch of experimentation. What looms ahead is the rewriting of healthcare's rules.

Partner, Health & Life Sciences, Oliver Wyman
Former Partner, Health & Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

How New Price Transparency Rules May Impact Payers and Providers

Immediate considerations for the industry.

Principal, Health and Life Sciences, Oliver Wyman
Global Head, Health Services, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Practice Leader, Oliver Wyman Actuarial Consulting

New competitors in healthcare are multiplying and scaling. But what will it take to win?

Director of Innovation, Atrium Health

Insights in your inbox

Subscribe